Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

Cited by (126)

Items 101–126 of 126

1. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma
   Trista K. Hinz, Anh T. Le, Tristan Doan, Abby Ast, Sophia Jaramillo, Jasalyn T. Avila, Daniel Skhisov, Samantha Haines, Andre Navarro, Tejas Patil et al. · 2026 · Cancer Letters
2. Novel Pyrazolo[3,4-b]pyrazines as SHP2 Inhibitors for Treating Cancer
   Ram W. Sabnis · 2021 · ACS Medicinal Chemistry Letters
3. Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3- and KIT- Mutant AML
   Bogdan Ovidiu Popescu, Carlos E. Stahlhut, Theodore C. Tarver, Sydney Wishner, Bianca J. Lee, Cheryl A.C. Peretz, Cuyler Luck, Paul J. Phojanakong, Juan A. Cámara, Henry Hongo et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
4. SHP2 binds directly to SOS1 to enable RAS activation
   Toshiyuki Araki, Yashika Agrawal, Sachin S. Katti, Hiep L.D. Nguyen, Daniel Pushparaju Yeggoni, Mitchell J. Geer, Wei Wei, Daniëlle T.J. Woutersen, Tieme Bijlsma, Cameron Genxuan Lian et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
5. Targeting a broad spectrum of KRAS -mutant cancers by hyperactivation-induced cell death
   Johanna Lilja, Jasmin Kaivola, James R. W. Conway, Joni Vuorio, Hanna Parkkola, Pekka Roivas, Taru Varila, Guillaume Jacquemet, Emilia Peuhu, Emily Wang et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
6. Analysis of communal Pathogenesis and Immune Infiltration Characteristics Between Psoriasis and Pulmonary Arterial Hypertension
   Qingyue Xia, Wenxing Su, Yuxin Cheng, ni zeng, Zhiyu Lu, Wenxing Su, Dan Luo · 2022 · Research Square
7. Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
   Giulia Franciosa, Jesper Velgaard Olsen · 2023 · Oncotarget
8. Molecular Docking Study of Oxido-Vanadium Complexes with Proteins Involved in Breast Cancer
   Lisset Noriega, María Eugenia Castro, Norma A. Caballero, Gabriel Merino, Francisco J. Meléndez · 2023 · Lecture notes in networks and systems
9. Targeted Therapies for Pancreatic Cancer
   Anirban Maitra · 2023 · Wiley eBooks
10. Analysis of the clinical characteristics and prognosis of adult de novo acute myeloid leukemia (none APL) with PTPN11 mutations
    Sheng Li, Yajiao Liu, Yingying Zhu, Jingfen Zhou, Haiying Hua · 2023 · Open Medicine
11. Exploring the effect of active site loops dynamics on PTP1B/SHP2 activity through selective benzamide-based inhibitors
    Qing Cao, Tian-Tian Zhao, Chun Zhang, Wenlong Wang · 2026 · Journal of Biomolecular Structure and Dynamics
12. Integrative In Silico Pipeline for Discovering Natural SHP2 Allosteric Inhibitors Against Leukaemia
    Manal A. Babaker, Mohammed A. Bazuhair · 2026 · ChemistrySelect
13. Autophagic Pathway on GABARAP Involved in GABAA Receptor Trafficking
    Mengqi Zhou, Wenjing Shi, Haoran Li, Jie Bai · 2026 · Neurochemical Research
14. Probing 3‐Amino‐2 H ‐Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2
    Machoud Amoussa, Nina‐Louisa Efrém, Feng Li, Ziqiong Guo, Yvette Roske, Katrin Jana Frank, Szymon Pach, Clemens Alexander Wolf, Feng Bo, Marina Lesina et al. · 2026 · ChemMedChem
15. Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro
    Ghalia Khoder, Rose Ghemrawi, Nour Sammani, Rania Harati, Mohamad Hamad, Jibran Sualeh Muhammad, Walaa Mousa, Mostafa Khair · 2026 · PLoS ONE
16. Diagnostic Lag in Precision Medicine
    Petr Heneberg · 2026 · Clinical Pharmacology & Therapeutics
17. Fragment-Based Covalent Targeting of Lysines at the Allosteric Latch Site of SHP2
    V. di Lorenzo, Noémi Csorba, Renáta Szabó, Levente Kollár, Yvette Roske, Ivan Ranđelović, Krisztina Balázs, Tibor Viktor Szalai, Nina‐Louisa Efrém, Levente M. Mihalovits et al. · 2026 · Journal of Medicinal Chemistry
18. Protein degraders targeting JAK/STAT3 signaling pathway are emerging therapeutic modalities for human cancers
    Xinyu Feng, Nanjing Li, Xiaorong Chen, Xinyue Cao, Jingling Dai, Shaoquan Xiong, Zhu Yuan · 2026 · Biochemical Pharmacology
19. BindingDB Entry 50017101: Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
    BindingDB · 2023 · UC San Diego
20. BindingDB Entry 50022381: Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors.
    BindingDB · 2025 · UC San Diego
21. BindingDB Entry 50021137: HDAC-targeting epigenetic modulators for cancer immunotherapy.
    BindingDB · 2025 · UC San Diego
22. BindingDB Entry 50014505: Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.
    BindingDB · 2022 · UC San Diego
23. BindingDB Entry 50021909: Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment.
    BindingDB · 2025 · UC San Diego
24. BindingDB Entry 50022804: Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules.
    BindingDB · 2026 · UC San Diego
25. BindingDB Entry 50016243: Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
    BindingDB · 2023 · UC San Diego
26. BindingDB Entry 50021399: Design, Synthesis and Antitumor Activity of a Novel Class of SHP2 Allosteric Inhibitors with a Furanyl Amide-Based Scaffold.
    BindingDB · 2025 · UC San Diego